Survival curves. OS curves as estimated in the Markov model for both Model A and Model B. Estimated survival curves include treatment effects of both first- and second-line treatment. (A) VenO and ClbO⁹ and subsequent second-line treatment.^21,22 (B) VenO and ibrutinib (Ibr) based on the NMA²⁴ and subsequent therapy.^21,22 The dashed line indicates the change from data extracted directly from clinical trial (A) or NMA (B) to parametric extrapolation.